Fibrocell Science, Inc. is a company that specialises in developing autologous cell therapies for skin and connective tissue diseases that have unmet medical needs. Its proprietary autologous fibroblast technology is used in the development of azficel-T, which is currently undergoing Phase II clinical trials for the treatment of vocal cord scarring and restrictive burn scarring.
Fibrocell Science Inc's ticker is FCSC
The company's shares trade on the NASDAQ stock exchange
They are based in Exton, Pennsylvania
There are 51-200 employees working at Fibrocell Science Inc
It is http://www.fibrocellscience.com/
Fibrocell Science Inc is in the Healthcare sector
Fibrocell Science Inc is in the Drugs - Generic industry
The following five companies are Fibrocell Science Inc's industry peers: